| Q57666978 | A phase II−III trial of olesoxime in subjects with amyotrophic lateral sclerosis |
| Q58271878 | A post hoc analysis of subgroup outcomes and creatinine in the phase III clinical trial (EMPOWER) of dexpramipexole in ALS |
| Q46595019 | A randomized, placebo-controlled, double-blind phase IIb trial evaluating the safety and efficacy of tirasemtiv in patients with amyotrophic lateral sclerosis |
| Q48266568 | A rapid functional decline type of amyotrophic lateral sclerosis is linked to low expression of TTN. |
| Q38573829 | A retrospective review of the progress in amyotrophic lateral sclerosis drug discovery over the last decade and a look at the latest strategies |
| Q34554820 | ALS Clinical Trials Review: 20 Years of Failure. Are We Any Closer to Registering a New Treatment? |
| Q38170698 | ALS and neuromuscular disease: in search of the Holy Grail |
| Q97519933 | Abnormal Mitochondrial Quality Control in Neurodegenerative Diseases |
| Q56839346 | Amyotrophic Lateral Sclerosis: An Aging-Related Disease |
| Q30251559 | Amyotrophic lateral sclerosis and motor neuron syndromes in Asia |
| Q47782678 | An assessment of treatment guidelines, clinical practices, demographics, and progression of disease among patients with amyotrophic lateral sclerosis in Japan, the United States, and Europe |
| Q38947718 | Assessment of Motor Units in Neuromuscular Disease. |
| Q46084639 | Association Between Decline in Slow Vital Capacity and Respiratory Insufficiency, Use of Assisted Ventilation, Tracheostomy, or Death in Patients With Amyotrophic Lateral Sclerosis |
| Q93120139 | Autologistic network model on binary data for disease progression study |
| Q38783403 | Automated telephone communication systems for preventive healthcare and management of long-term conditions |
| Q38646588 | Blood-Brain Barrier Driven Pharmacoresistance in Amyotrophic Lateral Sclerosis and Challenges for Effective Drug Therapies. |
| Q28550359 | Bromocriptine Mesylate Attenuates Amyotrophic Lateral Sclerosis: A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Research in Japanese Patients |
| Q35501852 | Clinical Measures of Disease Progression in Amyotrophic Lateral Sclerosis |
| Q38260277 | Clinical trials in amyotrophic lateral sclerosis: why so many negative trials and how can trials be improved? |
| Q48168716 | Comment on: The Awaji criteria are not always superior to the previous criteria: A meta-analysis |
| Q35064956 | Commonalities and challenges in the development of clinical trial measures in neurology |
| Q51733178 | Comparing methods to combine functional loss and mortality in clinical trials for amyotrophic lateral sclerosis. |
| Q36385882 | Covariate-adjusted borrowing of historical control data in randomized clinical trials. |
| Q91775486 | Critical design considerations for time-to-event endpoints in amyotrophic lateral sclerosis clinical trials |
| Q88774888 | DNA Damage Response and Repair, DNA Methylation, and Cell Death in Human Neurons and Experimental Animal Neurons Are Different |
| Q88608121 | Dexpramipexole as an oral steroid-sparing agent in hypereosinophilic syndromes |
| Q48256015 | Dexpramipexole improves bioenergetics and outcome in experimental stroke |
| Q34744144 | Dexpramipexole is ineffective in two models of ALS related neurodegeneration |
| Q49335981 | Disease-modifying and symptomatic treatment of amyotrophic lateral sclerosis |
| Q41908695 | Embracing Biological and Methodological Variance in a New Approach to Pre-Clinical Stroke Testing |
| Q52651163 | Energy metabolism in ALS: an underappreciated opportunity? |
| Q35891811 | Erythropoietin in amyotrophic lateral sclerosis: a multicentre, randomised, double blind, placebo controlled, phase III study |
| Q38223292 | Experimental trials in amyotrophic lateral sclerosis: a review of recently completed, ongoing and planned trials using existing and novel drugs |
| Q47815494 | Exploring the diagnosis delay and ALS functional impairment at diagnosis as relevant criteria for clinical trial enrolment |
| Q39000702 | Fixed dynamometry is more sensitive than vital capacity or ALS rating scale |
| Q39033841 | Fluid-Based Biomarkers for Amyotrophic Lateral Sclerosis |
| Q34741619 | GNX-4728, a novel small molecule drug inhibitor of mitochondrial permeability transition, is therapeutic in a mouse model of amyotrophic lateral sclerosis |
| Q92813735 | Glial Cells-The Strategic Targets in Amyotrophic Lateral Sclerosis Treatment |
| Q87384369 | High-calorie diets in amyotrophic lateral sclerosis |
| Q91801500 | Imaging Mass Spectrometry: A New Tool to Assess Molecular Underpinnings of Neurodegeneration |
| Q55054303 | Improved stratification of ALS clinical trials using predicted survival. |
| Q36679757 | Intraspinal stem cell transplantation for amyotrophic lateral sclerosis |
| Q39101800 | Metabolic Dysfunctions in Amyotrophic Lateral Sclerosis Pathogenesis and Potential Metabolic Treatments |
| Q60949835 | Metabolomics Biomarkers: A Strategy Toward Therapeutics Improvement in ALS |
| Q91048657 | Modeling sporadic ALS in iPSC-derived motor neurons identifies a potential therapeutic agent |
| Q47688852 | Monitoring disease progression with plasma creatinine in amyotrophic lateral sclerosis clinical trials |
| Q45869420 | Motoneuron Disease: Clinical |
| Q38417288 | Motor neuron disease-frontotemporal dementia: a clinical continuum |
| Q47180993 | Myeloablative Autologous Stem-Cell Transplantation for Severe Scleroderma |
| Q90558252 | Neuroprotection Induced by Dexpramipexole Delays Disease Progression in a Mouse Model of Progressive Multiple Sclerosis |
| Q33783000 | New Therapeutics to Modulate Mitochondrial Function in Neurodegenerative Disorders |
| Q26799600 | Novel Therapies for Eosinophilic Disorders |
| Q38868221 | Novel therapies in development that inhibit motor neuron hyperexcitability in amyotrophic lateral sclerosis |
| Q41837997 | Outcome measures in amyotrophic lateral sclerosis clinical trials |
| Q48033726 | Pharmacokinetic profile of edaravone: a comparison between Japanese and Caucasian populations |
| Q48033706 | Post-hoc analysis of randomised, placebo-controlled, double-blind study (MCI186-19) of edaravone (MCI-186) in amyotrophic lateral sclerosis |
| Q57393246 | Prognosis for patients with amyotrophic lateral sclerosis: development and validation of a personalised prediction model |
| Q42175195 | Quantitative strength testing in ALS clinical trials |
| Q57147110 | Reducing sample size requirements for future ALS clinical trials with a dedicated electrical impedance myography system |
| Q61807447 | Refining eligibility criteria for amyotrophic lateral sclerosis clinical trials |
| Q64086441 | Revised Airlie House consensus guidelines for design and implementation of ALS clinical trials |
| Q92376753 | Risk Factors and Emerging Therapies in Amyotrophic Lateral Sclerosis |
| Q92436561 | Ropinirole hydrochloride remedy for amyotrophic lateral sclerosis - Protocol for a randomized, double-blind, placebo-controlled, single-center, and open-label continuation phase I/IIa clinical trial (ROPALS trial) |
| Q34436090 | Safety and efficacy of ceftriaxone for amyotrophic lateral sclerosis: a multi-stage, randomised, double-blind, placebo-controlled trial |
| Q40358058 | Safety and efficacy of ozanezumab in patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled, phase 2 trial |
| Q56967077 | Safety and efficacy of rasagiline as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomised, double-blind, parallel-group, placebo-controlled, phase 2 trial |
| Q28538939 | Safety, pharmacokinetic, and functional effects of the nogo-a monoclonal antibody in amyotrophic lateral sclerosis: a randomized, first-in-human clinical trial |
| Q40563709 | Serum urate at trial entry and ALS progression in EMPOWER. |
| Q42369773 | Shortcomings in the Current Amyotrophic Lateral Sclerosis Trials and Potential Solutions for Improvement |
| Q51741753 | Stage at which riluzole treatment prolongs survival in patients with amyotrophic lateral sclerosis: a retrospective analysis of data from a dose-ranging study. |
| Q61444288 | Stratification of amyotrophic lateral sclerosis patients: a crowdsourcing approach |
| Q38947721 | Strength Testing in Motor Neuron Diseases |
| Q28659882 | Subjects no more: what happens when trial participants realize they hold the power? |
| Q38218666 | The ER mitochondria calcium cycle and ER stress response as therapeutic targets in amyotrophic lateral sclerosis. |
| Q89870358 | The First Frontier: Digital Biomarkers for Neurodegenerative Disorders |
| Q41052218 | The MITOS system predicts long-term survival in amyotrophic lateral sclerosis |
| Q34389199 | The National ALS Registry: a recruitment tool for research |
| Q38667538 | The clinical landscape for SMA in a new therapeutic era. |
| Q89645812 | The clinical trial landscape in amyotrophic lateral sclerosis-Past, present, and future |
| Q38841508 | The entangled ER-mitochondrial axis as a potential therapeutic strategy in neurodegeneration: A tangled duo unchained |
| Q43409823 | The murky path to drug discovery in ALS becomes clearer |
| Q38380170 | The promise of futility trials in neurological diseases. |
| Q58274610 | Theme 3 Biomarkers and Outcome Measures |
| Q48492659 | Therapy of amyotrophic lateral sclerosis remains a challenge |
| Q58005566 | Time to generalization and prediction of survival in patients with amyotrophic lateral sclerosis: a retrospective observational study |
| Q64075393 | Tracking a Fast-Moving Disease: Longitudinal Markers, Monitoring, and Clinical Trial Endpoints in ALS |
| Q47680014 | Trajectories of impairment in amyotrophic lateral sclerosis: Insights from the Pooled Resource Open-Access ALS Clinical Trials cohort |
| Q38542939 | Transcriptional analysis reveals distinct subtypes in amyotrophic lateral sclerosis: implications for personalized therapy |
| Q50222481 | What can we learn from the edaravone development program for ALS? |
| Q89205396 | When a negative trial in ALS has a positive effect on research |